: Maintaining a Strong Buy outlook due to potential 2026 milestones . Top Biotech Stocks by Analyst Consensus
Several biotechnology companies have recently earned ratings from analysts as of April 28, 2026. These ratings are often driven by positive clinical trial progress, strategic acquisitions, or analyst upgrades following strong performance. Latest Analyst "Strong Buy" Upgrades strong buy biotech stocks
: Upgraded to Strong Buy by Truist Financial and BTIG Research . : Maintaining a Strong Buy outlook due to